Page 2325 - Williams Hematology ( PDFDrive )

2298 Part XII: Hemostasis and Thrombosis Chapter 134: Atherothrombosis: Disease Initiation, Progression, and Treatment 2299

45. Nozaki T, Sugiyama S, Koga H, et al: Significance of a multiple biomarkers strategy 76. Binder CJ, Chang MK, Shaw PX, et al: Innate and acquired immunity in atherogenesis.
including endothelial dysfunction to improve risk stratification for cardiovascular Nat Med 8:1218–1226, 2002.
events in patients at high risk for coronary heart disease. J Am Coll Cardiol 54:601–608, 77. Medzhitov R: Toll-like receptors and innate immunity. Nat Rev Immunol 1:135–145,
2009. 2001.
46. Liuba P, Karnani P, Pesonen E, et al: Endothelial dysfunction after repeated Chlamydia 78. Erridge C: The roles of pathogen-associated molecular patterns in atherosclerosis.
pneumoniae infection in apolipoprotein E-knockout mice. Circulation 102:1039–1044, Trends Cardiovasc Med 18:52–56, 2008.
2000. 79. Medzhitov R, Janeway CA Jr: Decoding the patterns of self and nonself by the innate
47. Fichtlscherer S, Rosenberger G, Walter DH, et al: Elevated C-reactive protein levels and immune system. Science 296:298–300, 2002.
impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation 80. Ridker PM: Clinical application of C-reactive protein for cardiovascular disease detec-
102:1000–1006, 2000. tion and prevention. Circulation 107:363–369, 2003.
48. Beckman JA, Ganz J, Creager MA, et al: Relationship of clinical presentation and calcifi- 81. Dansky HM, Barlow CB, Lominska C, et al: Adhesion of monocytes to arterial endothe-
cation of culprit coronary artery stenoses. Arterioscler Thromb Vasc Biol 21:1618–1622, lium and initiation of atherosclerosis are critically dependent on vascular cell adhesion
2001. molecule-1 gene dosage. Arterioscler Thromb Vasc Biol 21:1662–1667, 2001.
49. Libby P, Ridker PM, Maseri A: Inflammation and atherosclerosis. Circulation 105: 82. Cybulsky MI, Iiyama K, Li H, et al: A major role for VCAM-1, but not ICAM-1, in early
1135–1143, 2002. atherosclerosis. J Clin Invest 107:1255–1262, 2001.
50. Moore KJ, Sheedy FJ, Fisher EA: Macrophages in atherosclerosis: A dynamic balance. 83. Collins RG, Velji R, Guevara NV, et al: P-Selectin or intercellular adhesion molecule
Nat Rev Immunol 13:709–721, 2013. (ICAM)-1 deficiency substantially protects against atherosclerosis in apolipoprotein
51. Takeshita J, Mohler ER, Krishnamoorthy P, et al: Endothelial cell-, platelet-, and mono- E-deficient mice. J Exp Med 191:189–194, 2000.
cyte/macrophage-derived microparticles are elevated in psoriasis beyond cardiometa- 84. Parks BW, Lusis AJ: Macrophage accumulation in atherosclerosis. N Engl J Med
bolic risk factors. J Am Heart Assoc 3:e000507, 2014. 369:2352–2353, 2013.
52. Lim S, Park S: Role of vascular smooth muscle cell in the inflammation of atherosclero- 85. Robbins CS, Hilgendorf I, Weber GF, et al: Local proliferation dominates lesional mac-
sis. BMB Rep 47:1–7, 2014. rophage accumulation in atherosclerosis. Nat Med 19:1166–1172, 2013.
53. Kanse SM, Parahuleva M, Muhl L, et al: Factor VII-activating protease (FSAP): Vascu- 86. Weber C, Noels H: Atherosclerosis: Current pathogenesis and therapeutic options. Nat
lar functions and role in atherosclerosis. Thromb Haemost 99:286–289, 2008. Med 17:1410–1422, 2011.
54. Fuster V: Lewis A. Conner Memorial Lecture. Mechanisms leading to myocardial 87. Zalewski A, Macphee C, Nelson JJ: Lipoprotein-associated phospholipase A2: A poten-
infarction: Insights from studies of vascular biology. Circulation 90:2126–2146, 1994. tial therapeutic target for atherosclerosis. Curr Drug Targets Cardiovasc Haematol
55. Schwartz SM, Murry CE: Proliferation and the monoclonal origins of atherosclerotic Disord 5:527–532, 2005.
lesions. Annu Rev Med 49:437–460, 1998. 88. Shi Y, Zhang P, Zhang L, et al: Role of lipoprotein-associated phospholipase A(2) in
56. Scott NA, Cipolla GD, Ross CE, et al: Identification of a potential role for the adventitia leukocyte activation and inflammatory responses. Atherosclerosis 191:54–62, 2006.
in vascular lesion formation after balloon overstretch injury of porcine coronary arteries. 89. Wilensky RL, Shi Y, Mohler ER 3rd, et al: Inhibition of lipoprotein-associated phos-
Circulation 93:2178–2187, 1996. pholipase A2 reduces complex coronary atherosclerotic plaque development. Nat Med
57. Sakakura K, Nakano M, Otsuka F, et al: Pathophysiology of atherosclerosis plaque 14:1059–1066, 2008.
progression. Heart Lung Circ 22:399–411, 2013. 90. Mohler ER 3rd, Ballantyne CM, Davidson MH, et al: The effect of darapladib on plasma
58. Majesky MW, Dong XR, Regan JN, Hoglund VJ: Vascular smooth muscle progenitor lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in
cells: Building and repairing blood vessels. Circ Res 108:365–377, 2011. patients with stable coronary heart disease or coronary heart disease risk equivalent:
59. Der Leyen HE, Gibbons GH, Morishita R, et al: Gene therapy inhibiting neointimal The results of a multicenter, randomized, double-blind, placebo-controlled study. J Am
vascular lesion: In vivo transfer of endothelial cell nitric oxide synthase gene. Proc Natl Coll Cardiol 51:1632–1641, 2008.
Acad Sci U S A 92:1137–1141, 1995. 91. Investigators S, White HD, Held C, et al: Darapladib for preventing ischemic events in
60. Dzau VJ, Braun-Dullaeus RC, Sedding DG: Vascular proliferation and atherosclerosis: stable coronary heart disease. N Engl J Med 370:1702–1711, 2014.
New perspectives and therapeutic strategies. Nat Med 8:1249–1256, 2002. 92. Smith JD, Trogan E, Ginsberg M, et al: Decreased atherosclerosis in mice deficient in
61. Bonta PI, Pols TW, de Vries CJ: NR4A nuclear receptors in atherosclerosis and vein- both macrophage colony-stimulating factor (op) and apolipoprotein E. Proc Natl Acad
graft disease. Trends Cardiovasc Med 17:105–111, 2007. Sci U S A 92:8264–8268, 1995.
62. Lemos PA, Lee CH, Degertekin M, et al: Early outcome after sirolimus-eluting stent 93. Endemann G, Stanton LW, Madden KS, et al: CD36 is a receptor for oxidized low den-
implantation in patients with acute coronary syndromes: Insights from the Rapamycin- sity lipoprotein. J Biol Chem 268:11811–11816, 1993.
Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. J Am 94. Steinberg D, Parthasarathy S, Carew TE, et al: Beyond cholesterol: Modifications of
Coll Cardiol 41:2093–2099, 2003. low-density lipoprotein that increase its atherogenicity. N Engl J Med 320:915–924, 1989.
63. Sagripanti A, Carpi A: Antithrombotic and prothrombotic activities of the vascular 95. Boring L, Gosling J, Cleary M, Charo IF: Decreased lesion formation in CCR2–/– mice
endothelium. Biomed Pharmacother 54:107–111, 2000. reveals a role for chemokines in the initiation of atherosclerosis. Nature 394:894–897,
64. van Der Meijden PE, van Schilfgaarde M, van Oerle R, Renne T, et al: Platelet- and 1998.
erythrocyte-derived microparticles trigger thrombin generation via factor XIIa. 96. Gu L, Okada Y, Clinton SK, et al: Absence of monocyte chemoattractant protein-1
J Thromb Haemost 10:1355–1362, 2012. reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell
65. Falati S, Liu Q, Gross P, et al: Accumulation of tissue factor into developing thrombi 2:275–281, 1998.
in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet 97. Gosling J, Slaymaker S, Gu L, et al: MCP-1 deficiency reduces susceptibility to athero-
P-selectin. J Exp Med 197:1585–1598, 2003. sclerosis in mice that overexpress human apolipoprotein B. J Clin Invest 103:773–778,
66. Feil R, Lohmann SM, de Jonge H, et al: Cyclic GMP-dependent protein kinases and the 1999.
cardiovascular system: Insights from genetically modified mice. Circ Res 93:907–916, 98. Hur J, Yang HM, Yoon CH, et al: Identification of a novel role of T cells in postnatal
2003. vasculogenesis: Characterization of endothelial progenitor cell colonies. Circulation
67. Gonzalez MA, Selwyn AP: Endothelial function, inflammation, and prognosis in 116:1671–1682, 2007.
cardiovascular disease. Am J Med 115 Suppl 8A:99S–106S, 2003. 99. Tang WH, Wu Y, Nicholls SJ, Hazen SL: Plasma myeloperoxidase predicts incident
68. Anderson TJ: Nitric oxide, atherosclerosis and the clinical relevance of endothelial dys- cardiovascular risks in stable patients undergoing medical management for coronary
function. Heart Fail Rev 8:71–86, 2003. artery disease. Clin Chem 57:33–39, 2011.
69. Tulis DA, Durante W, Liu X, et al: Adenovirus-mediated heme oxygenase-1 gene delivery 100. Sugiyama S, Okada Y, Sukhova GK, et al: Macrophage myeloperoxidase regulation
inhibits injury-induced vascular neointima formation. Circulation 104:2710–2715, by granulocyte macrophage colony- stimulating factor in human atherosclerosis and
2001. implications in acute coronary syndromes. Am J Pathol 158:879–891, 2001.
70. Sachais BS: Platelet-endothelial interactions in atherosclerosis. Curr Atheroscler Rep 101. Babior BM: Phagocytes and oxidative stress. Am J Med 109:33–44, 2000.
3:412–416, 2001. 102. Suzuki H, Kurihara Y, Takeya M, et al: A role for macrophage scavenger receptors in
71. Marcus AJ, Broekman MJ, Drosopoulos JH, et al: Metabolic control of excessive extra- atherosclerosis and susceptibility to infection. Nature 386:292–296, 1997.
cellular nucleotide accumulation by CD39/ecto-nucleotidase-1: Implications for ische- 103. Febbraio M, Podrez EA, Smith JD, et al: Targeted disruption of the class B scavenger
mic vascular diseases. J Pharmacol Exp Ther 305:9–16, 2003. receptor CD36 protects against atherosclerotic lesion development in mice. J Clin Invest
72. Landmesser U, Merten R, Spiekermann S, et al: Vascular extracellular superoxide 105:1049–1056, 2000.
dismutase activity in patients with coronary artery disease: Relation to endothelium- 104. Kodama T, Reddy P, Kishimoto C, Krieger M: Purification and characterization of a
dependent vasodilation. Circulation 101:2264–2270, 2000. bovine acetyl low density lipoprotein receptor. Proc Natl Acad Sci U S A 85:9238–9242,
73. Cooke JP: Does ADMA cause endothelial dysfunction? Arterioscler Thromb Vasc Biol 1988.
20:2032–2037, 2000. 105. Henriksen T, Mahoney EM, Steinberg D: Enhanced macrophage degradation of low
74. Mohler ER 3rd, Shi Y, Moore J, et al: Diabetes reduces bone marrow and circulating density lipoprotein previously incubated with cultured endothelial cells: Recogni-
porcine endothelial progenitor cells, an effect ameliorated by atorvastatin and indepen- tion by receptors for acetylated low density lipoproteins. Proc Natl Acad Sci U S A 78:
dent of cholesterol. Cytometry A 75:75–82, 2009. 6499–6503, 1981.
75. Foteinos G, Hu Y, Xiao Q, et al: Rapid endothelial turnover in atherosclerosis-prone 106. Steinbrecher UP, Parthasarathy S, Leake DS, Witztum JL, Steinberg D: Modification of
areas coincides with stem cell repair in apolipoprotein E-deficient mice. Circulation low density lipoprotein by endothelial cells involves lipid peroxidation and degradation
117:1856–1863, 2008. of low density lipoprotein phospholipids. Proc Natl Acad Sci U S A 81:3883–3887, 1984.

Kaushansky_chapter 134_p2281-2302.indd 2299 17/09/15 3:50 pm